索格列净治疗慢性心力衰竭的研究进展
Research progress of sotagliflozin in treatment of chronic heart failure
颉晓铭 1于彤 1刘永铭2
作者信息
- 1. 兰州大学第一临床医学院,兰州 730030
- 2. 兰州大学第一医院老年医学科,甘肃省老年疾病临床医学研究中心,兰州 730030
- 折叠
摘要
心力衰竭是一种严重的慢性进展性心脏疾病,有较高的发病率及死亡率.索格列净是一种新型的钠葡萄糖共转运蛋白-1/2抑制剂,可以同时抑制消化道及肾小管对葡萄糖的吸收.多项研究证实索格列净不仅在降低心力衰竭患者心血管死亡率及再住院率方面与钠葡萄糖共转运蛋白-2抑制剂同样有效,同时也可以降低心力衰竭患者卒中及心肌梗死的发生率.本文综述索格列净在治疗心力衰竭中的作用机制及研究进展,以期在未来心衰患者的临床治疗中提供帮助.
Abstract
Heart failure is a serious chronic progressive heart disease with high morbidity and mortality.Sotagliflozin is a novel sodium and glucose cotransporter-1/2 inhibitor,which can inhibit glucose absorption in the digestive tract and renal tubules at the same time.A number of studies have confirmed that sotagliflozin is not only as effective as sodium-glucose co-transporter-2 inhibitors in reducing cardiovascular mortality and rehospitalization rate in patients with heart failure,but also can reduce the incidence of stroke and myocardial infarction in patients with heart failure.This article reviews the mechanism and research progress of sotagliflozin in the treatment of heart failure,in order to provide help for the clinical treatment of patients with heart failure in the future.
关键词
心力衰竭/索格列净/钠葡萄糖共转运蛋白-1/2抑制剂Key words
heart failure/sotagliflozin/sodium-glucose cotransporter-1/2 inhibitor引用本文复制引用
基金项目
甘肃省重点研发计划(20YF8FA079)
出版年
2024
NETL
NSTL
万方数据